Martin Holst Lange, executive vice president for Development at Novo Nordisk, stated, Novo Nordisk continues to evolve its focus beyond diabetes and obesity towards a broader spectrum of metabolic and cardiovascular health
PlexusDx patients often remain on tirzepatide for 12 to 36 months, though some continue indefinitely depending on their response, health status, and personal preference
(2001) Endocrinology Study in GH receptor-knockout mice demonstrating AOD 9604 lipolytic activity independent of classical GH signaling
These lifestyle adjustments complement the bodys natural adaptation to lower calorie intake, reduced body fat, and metabolic changes, helping most patients feel warmer and more comfortable during their treatment journey
Progress in Brain Research, 185 , 105-129
These outcomes have contributed to its widespread adoption in structured weight loss programs